GW Pharmaceuticals (GWPH) Soared To A 3-Month High On Phase 3 Study Results

GW Pharmaceuticals plc (GWPH) announced Monday morning that its Phase 3 study of Epidiolex, for the treatment of Dravet syndrome, met the primary endpoint of a significant reduction in convulsive seizures.

from RTT - Before the Bell http://ift.tt/1nKUv84
via IFTTT